Vor Biopharma (NASDAQ:VOR) Posts Quarterly Earnings Results, Misses Expectations By $0.64 EPS

Vor Biopharma (NASDAQ:VOR) announced its quarterly earnings data on Friday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.64), FiscalAI reports.

Vor Biopharma Price Performance

Shares of VOR stock traded down $1.26 during midday trading on Friday, reaching $19.65. 452,986 shares of the company traded hands, compared to its average volume of 1,044,427. Vor Biopharma has a 1-year low of $6.50 and a 1-year high of $26.76. The firm’s 50 day simple moving average is $20.82 and its two-hundred day simple moving average is $17.31.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on VOR. Wedbush raised their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. William Blair started coverage on shares of Vor Biopharma in a research note on Wednesday, October 21st. They set an “outperform” rating on the stock. Weiss Ratings raised shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Citigroup upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, October 15th. Finally, Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VOR. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Vor Biopharma during the 3rd quarter worth about $58,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Vor Biopharma by 25.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock valued at $198,000 after purchasing an additional 2,171 shares during the last quarter. Engineers Gate Manager LP increased its holdings in shares of Vor Biopharma by 37.5% during the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock worth $680,000 after buying an additional 10,071 shares during the last quarter. Braidwell LP raised its position in shares of Vor Biopharma by 22.8% in the 2nd quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after buying an additional 106,330 shares during the period. Finally, Wellington Management Group LLP purchased a new position in shares of Vor Biopharma in the 2nd quarter worth $499,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.